Evidence map›Paper›PMID 38400681›Full record

ArticleCancer medicine2024

Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early-stage, solitary and small (≤3 cm) treatment-naïve hepatocellular carcinoma.

A M Maher, M Shanker, H Y H Liu, Y Lee, D Leggett, P Hodgkinson, D Pryor, K A Stuart

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

A M MaherGastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID 0000-0002-7599-7613
M ShankerFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
H Y H LiuFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
Y LeeFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
D LeggettFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
P HodgkinsonFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
D PryorFaculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
K A StuartGastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
The University of Queensland · AUQueensland Police Service · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStereotactic body radiation therapy (SBRT) is associated with high local control rates in hepatocellular carcinoma (HCC). This study reports the outcomes of SBRT compared to surgical resection (SR) and percutaneous ablation (PA) for treatment-naïve, solitary HCCs ≤3 cm.

methodsThis was a retrospective study of patients with BCLC stage 0/A HCC with a single ≤3 cm lesion, treated with curative intent between 2016 and 2020. SBRT was used for patients considered unsuitable for SR or PA. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints were treatment-related clinical toxicity rates and local control (LC) rates.

resultsThere were 112 patients included in this study. SBRT was delivered in 36 patients (32.1%), 51 had PA (45.5%) and 25 underwent SR (22.3%). Median follow-up was 23 months (range, 3-60 months) from diagnosis. The 3-year PFS and OS were 67% and 69% following SBRT, 55% and 80% following PA, and 85% and 100% following SR, respectively. Patients in the SR cohort had significantly better 3-year PFS and OS compared to SBRT and PA groups (p = 0.03 and p = 0.04, respectively). There was no significant difference in PFS (p = 0.15) or OS (p = 0.23) between SBRT and PA treated patients. The 3-year LC rate for the entire cohort was 98%.

conclusionsIn patients with treatment-naïve, early-stage solitary HCCs ≤3 cm, SBRT was associated with comparable PFS, OS and LC outcomes to PA. SBRT should be considered as a curative intent therapy to avoid treatment stage migration in this favourable prognostic cohort of patients.

Indexed as

Carcinoma, HepatocellularCatheter AblationLiver NeoplasmsRadiosurgeryHumansRetrospective StudiesTreatment Outcomehepatocellular carcinoma (clinical)hepatocellular carcinoma (treatment)hepatology

Identifiers

PMID38400681
PMCPMC10891469
OpenAlexW4392133433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.